Antibacterial The end of bacterial resistance.
Patented methylglyoxal disrupts the bacterial cell wall through a multi-site mechanism pathogens cannot route around. No evolutionary resistance observed across two decades.
Clinical-stage pharmaceutical platform Est. 2023
The end of bacterial
resistance.
Logix Biosciences develops a patented class of structurally disruptive antimicrobials, engineered to defeat resistant bacteria, act as an effective antiviral, and drive angiogenic tissue repair.
20+ yrs
No observed evolutionary resistance
2
Parallel patented assets, botanical + synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
One engine, three fronts
One composition.
Three therapeutic fronts.
A single patented engine, methylglyoxal, expressed across three modes of action. Not a pipeline of unrelated molecules: one structurally disruptive composition, three ways to deploy it.
Antibacterial 
Antiviral An effective antiviral.
The same composition acts against enveloped respiratory viruses at the point of entry, neutralizing them before infection takes hold.
Angiogenic An effective angiogenic.
Beyond defense, the composition promotes angiogenesis and accelerates tissue repair, driving a regenerative wound-healing pathway.
The platform
Not one molecule.
A patented platform.
Two independently patented compositions, one botanical and one synthetic, multiply delivery options and de-risk capital across parallel clinical pathways. Both express the same patented methylglyoxal composition.
Asset 01
Botanical matrixLepto242
- Composition
- Patented Medical Grade Manuka composition, a botanical matrix.
- Human use
- Three decades of broad global human use of the natural composition from which Lepto242 is derived.
- FDA pathway
- 505(b)1 botanical pathway, qualifying on prior human use.
Asset 02
Synthetic small moleculeLgx242
- Composition
- Synthetic methylglyoxal derivative, engineered for precision delivery.
- Designation
- QIDP under the GAIN Act: +5 years exclusivity and Fast Track.
- FDA pathway
- LPAD pathway, scaling trial burden to a resistant population.
Mission
To usher in the Post-Resistance Era by delivering safe, structurally disruptive antimicrobials to millions of patients globally.
Contact
For scientific, regulatory,
and partnership inquiries.
- Phone
- +1 (800) 916-1220
- Office
- Monterey, California, United States